Company profile for Latigo Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Latigo Biotherapeutics is a clinical-stage enterprise dedicated to pioneering innovative non-opioid pain medications distinguished by their best-in-class profiles. Our efforts at Latigo are grounded in proprietary in-house research and unique insights. Beginning with advanced models, human biological understanding, and a distinctive discovery engine, we stand out, providing unparalleled potential for best-in-class solutions. W...
Latigo Biotherapeutics is a clinical-stage enterprise dedicated to pioneering innovative non-opioid pain medications distinguished by their best-in-class profiles. Our efforts at Latigo are grounded in proprietary in-house research and unique insights. Beginning with advanced models, human biological understanding, and a distinctive discovery engine, we stand out, providing unparalleled potential for best-in-class solutions. With several groundbreaking pain programs currently in the discovery and development stages, we leverage our internal ion channel expertise to offer exceptional best-in-class possibilities.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Thousand Oaks, CA 91320
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/latigo-biotherapeutics-closes-150-million-in-series-b-financing-to-advance-non-opioid-pain-therapeutics-302397457.html

PR NEWSWIRE
17 Mar 2025

https://www.prnewswire.com/news-releases/latigo-biotherapeutics-granted-fda-fast-track-designation-for-ltg-001--potential-best-in-class-nav1-8-inhibitor-for-the-non-opioid-treatment-of-acute-pain-302387994.html

PR NEWSWIRE
03 Mar 2025

https://www.prnewswire.com/news-releases/latigo-biotherapeutics-appoints-industry-veteran-timothy-p-walbert-as-board-chair-302309161.html

PR NEWSWIRE
19 Nov 2024

https://www.fiercebiotech.com/cro/pain-medicine-biotech-latigo-taps-cro-founder-cmo-role

FIERCE BIOTECH
20 Aug 2024

https://www.prnewswire.com/news-releases/latigo-biotherapeutics-announces-positive-phase-1-data-for-lead-non-opioid-pain-medicine-candidate-and-appoints-neil-singla-md-chief-medical-officer-302224151.html

PR NEWSWIRE
19 Aug 2024
Latigo Biotherapeutics Names New CEO
Latigo Biotherapeutics Names New CEO

22 Jul 2024

// CONTRACT PHARMA

https://www.contractpharma.com/contents/view_breaking-news/2024-07-22/latigo-biotherapeutics-names-new-ceo/?widget=listSection

CONTRACT PHARMA
22 Jul 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty